A combination of pills that cures 9 of 10 hepatitis C patients and is well tolerated by patients, reveals a new study.
Researchers from the University of Texas Health Science Center at San Antonio found the combination of the drugs sofosbuvir and simeprevir, with or without ribavirin that cured 93 percent of patients in 12 weeks.
Lead researcher, Eric Lawitz, said that they were now in the midst of a paradigm shift of moving away from complicated injection regimens that included interferon and often caused significant side effects with modest success rates.
Lawitz added that this trial provided a glimpse into the outcomes of sofosbuvir and simeprevir for treatment of hepatitis C and both drugs were approved by the FDA but were not yet approved together for this treatment.
This study is published in The Lancet.